- Oral insulin program continues to advance with topline efficacy data expected in H2 2022 - Significant value creation opportunities through oral COVID-19 vaccine program and partnerships - Well positioned to capitalize on opportunities with strong cash balance of ~$174 million as of December 3, [...]
- Protease inhibitor is a key component of Oramed's PODTM technology that protects therapeutic proteins in the digestive system - Oramed has already been granted this patent in the United States and Japan NEW YORK, Jan. 5, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) [...]
Initial pre-purchase of 10 million doses of oral vaccines with a potential deal for further orders worth hundreds of millions of dollars Prospective patient population of approximately 660 million throughout the Association of Southeast Asian Nations NEW YORK, Dec. 29, 2021 /PRNewswire/ -- Oramed Pharmaceuticals [...]
Oravax's oral vaccine targets three surface proteins, making it potentially more effective against current and future variants Oravax's oral vaccine should offer critical advantages, including logistics, distribution and delivery in less vaccinated regions, including Africa NEW YORK, Dec. 14, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. [...]
NEW YORK, Dec. 8, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced the appointment of Netanel Derovan to serve as Chief Legal Officer (General Counsel) and Company Secretary, [...]
NEW YORK, Nov. 24, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, announced today that its common stock will be added to the MSCI USA Small Cap Index effective [...]
NEW YORK, Nov. 23, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has enrolled and randomized over 75% of the 675 patients planned for its [...]
- Millions of people in the region could benefit from the COVID-19 vaccine candidate- faster, easier, without the cold chain: The Oravax Oral Vaccine - The new partnership builds on the respective strengths of Oravax Medical and Genomma Lab to create compelling value for both [...]
NEW YORK, November 11, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Chief Executive Officer Nadav Kidron will present a company overview at the H.C. Wainwright [...]
NEW YORK, Nov. 8, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. ("Oramed" or the "Company") (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that it has closed its previously announced registered direct offering of 2,000,000 shares [...]